Shopping Cart
- Remove All
- Your shopping cart is currently empty
KIRA-7 is an imidazopyrazine compound. KIRA-7 has an anti-fibrotic effect. KIRA-7 binds the IRE1α kinase (IC50: 110 nM) to allosterically inhibit its RNase activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,370 | 6-8 weeks | |
50 mg | $1,780 | 6-8 weeks | |
100 mg | $2,800 | 6-8 weeks |
Description | KIRA-7 is an imidazopyrazine compound. KIRA-7 has an anti-fibrotic effect. KIRA-7 binds the IRE1α kinase (IC50: 110 nM) to allosterically inhibit its RNase activity. |
Targets&IC50 | IRE1α kinase:110 nM |
In vitro | In the alveolar epithelial cell line MLE12, KIRA-7 inhibits XBP1 splicing [1]. |
In vivo | After Bleomycin exposure, mRNA levels of BiP and CHOP are significantly elevated, and treatment of Bleomycin-exposed mice with KIRA-7 decreased these levels. KIRA-7 (5 mg/kg; intraperitoneal injection; daily for 14 days; C57BL6 mice) treatment causes decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice treated with vehicle. mRNA levels of collagen 1A1 and fibronectin are both significantly decreased by KIRA-7 treatment [1]. |
Molecular Weight | 466.51 |
Formula | C27H23FN6O |
Cas No. | 1937235-76-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.